Recognising the Broader Value of Meningococcal Vaccination: A Matter of Evidence, Ability or Willingness?
Author(s)
Akerjord S1, Neri M2, Brassel S2, Steuten L3, Schley K4, Charos A5
1Pfizer ltd, London, LON, UK, 2Office of Health Economics, London, UK, 3Office of Health Economics, London, LON, UK, 4Pfizer Deutschland GmbH, Berlin, BE, Germany, 5Pfizer ltd, Tadworth, UK
Presentation Documents
OBJECTIVES:
It is widely argued that the value of meningococcal vaccination extends beyond the narrow value elements traditionally considered in health technology assessment. However, measuring broader value presents challenges, while assessment methods and outcomes vary widely. This paper investigates the extent to which the broader value of meningococcal vaccination is recognised, considering the available evidence and decision maker’s methodological ability and willingness.METHODS:
A targeted literature review informed the classification of broader value elements according to their relevance to meningococcal vaccination and the quality of existing evidence. Focusing on relevant value elements with good evidentiary standards, decision-makers' perspectives and methodological ability to consider them were assessed through case studies of HTA of meningococcal B vaccination in England and the Netherlands.RESULTS:
Value elements of high relevance to meningococcal vaccination with good quality evidence include caregivers' health gains, patients' lifetime productivity gains, and disease severity. The willingness and methodological ability to incorporate them into value assessments have been mixed. This is attributable to the scope of the value assessment perspective, and the use of evaluation methods that do not fully capture broader value. For other broader value elements, evidence gaps are another potential barrier to value demonstration and recognition.CONCLUSIONS:
The current evidence base confirms that the value of meningococcal vaccination spans beyond healthcare sector effects to health-related externalities, allocative value and societal economic benefits. To ensure that the most efficient resource allocation outcomes are achieved, countries should consider how to improve their perspective and methodological ability to assess broader value elements accurately.Conference/Value in Health Info
2022-11, ISPOR Europe 2022, Vienna, Austria
Value in Health, Volume 25, Issue 12S (December 2022)
Code
EE351
Topic
Economic Evaluation, Health Technology Assessment
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis, Novel & Social Elements of Value, Value Frameworks & Dossier Format
Disease
No Additional Disease & Conditions/Specialized Treatment Areas